I am not sure the extent of information that has been shared with EMA, specially around latest data on AIPAC, but you would think, even if that data was not "presented" to EMA, they would have been part of scientific consideration in formulating IBM'S questions for EMA, and discussions and the step achieved now. I would doubt if the results were not good, IMM would risk its footing with EMA (&FDA) by just jump the gun. So, another indicationAIPAC data is exciting and/as leading us to phase III, passing the "bottle neck" Ph II, as known in the clinic trial world.
Please also know that fast tracking status is/was a VIP access to EMA/FDA for advice. This may well be some of the benefit already.
- Forums
- ASX - By Stock
- IMM
- Ann: Immutep receives EMA scientific advice for Phase 3 in MBC
Ann: Immutep receives EMA scientific advice for Phase 3 in MBC, page-9
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
38.0¢ |
Change
0.010(2.70%) |
Mkt cap ! $551.9M |
Open | High | Low | Value | Volume |
37.0¢ | 39.0¢ | 37.0¢ | $1.296M | 3.401M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 54900 | 37.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
38.0¢ | 22008 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 54900 | 0.375 |
5 | 90652 | 0.370 |
4 | 133026 | 0.365 |
5 | 48561 | 0.360 |
6 | 66776 | 0.355 |
Price($) | Vol. | No. |
---|---|---|
0.380 | 22008 | 1 |
0.385 | 574526 | 4 |
0.390 | 300273 | 9 |
0.395 | 166772 | 7 |
0.400 | 268030 | 8 |
Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
UNT
UNITH LTD
Idan Schmorak, CEO
Idan Schmorak
CEO
Previous Video
Next Video
SPONSORED BY The Market Online